The UK Adrenoleukodystrophy (ALD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP). Adrenoleukodystrophy is a result of fatty acid build-up caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
Adrenoleukodystrophy is a fatal progressive neurogenerative disorder affecting brain white matter. Adrenoleukodystrophy is most commonly observed in childhood and present in both males and females; mainly affects men. The major categories of ALD are childhood cerebral ALD (CCALD), adult cerebral ALD, adrenomyeloneuropathy (AMN), and Addison’s disease. The incidence varying between 0.8 and 4.76 people affected per 100,000 births while the prevalence of ALD is estimated to lie between 1 in 10,000 and 1 in 17,000 individuals.
Market Growth Drivers
The surge in the number of patients is driving the market growth of adrenoleukodystrophy. Rising awareness about adrenoleukodystrophy leads to an increase in potential in research treatment. Moreover, the rise in support and funds for research into new ALD treatments contribute to driving the market growth during the forecast period.
The key industry players are engaged in the development of new products by investment in research & development owing to a rise in the demand for products. This, in turn, is estimated to drive market growth.
Government initiatives to improve healthcare infrastructure leads to an increase the patient access and thereby offers a significant opportunity in the market. Moreover, investment by key players to address the unmet medical needs is providing considerable opportunity in the market which will drive the market growth during the forecast period.
However, the high cost of treatment of adrenoleukodystrophy disease and side-effects associated with stem cell therapy and corticosteroid replacement therapy is expected to hamper the ALD treatment market growth during the forecast period.